Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FV5BC
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,786
Award facts
- Contract value 100% obligated
- $3,785.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $3,785.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector medications. The delivery order, which became effective on October 27, 2025, carries an ultimate completion date of October 28, 2025, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. is the sole awardee with no identified subcontractors involved in this delivery order.
This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply comprehensive pharmaceutical and medical consumables to Department of Defense healthcare facilities worldwide. The underlying IDC, designated SPE2DR and valued at $499,999,999, positions DMS Pharmaceutical Group as a regional prime vendor contractor with authorization to deliver firm fixed-price orders for branded and generic prescription drugs, biologics, and medical consumables through December 31, 2036. DMS Pharmaceutical Group has demonstrated substantial federal contracting activity across diverse pharmaceutical categories, making it a critical supplier within the military medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FV5BC?
SPE2DB26FV5BC was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FV5BC worth?
The government has obligated $3,786 on SPE2DB26FV5BC.
Is contract SPE2DB26FV5BC an order under another contract?
Yes. SPE2DB26FV5BC is a delivery order under SPE2DB22D9206, an indefinite delivery contract.
Was contract SPE2DB26FV5BC competed?
The extent of competition for SPE2DB26FV5BC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award